Literature DB >> 9806900

Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases.

K J Bame1, A Hassall, C Sanderson, I Venkatesan, C Sun.   

Abstract

Heparanases are mammalian endoglycosidases that cleave heparan sulphate glycosaminoglycans from proteoglycan core proteins and degrade them into shorter chains. The enzymes have been proposed to act in a variety of cellular processes, including proteoglycan catabolism, remodelling of basement membranes and release of heparan sulphate-binding ligands from their extracellular storage sites. Additional functions for heparanases may be to generate short heparan sulphate chains that stabilize or activate other proteins. While heparanase activities have been described in a number of tissues and cell lines, it is not known how many different enzymes are responsible for these activities. Our recent studies characterizing the short glycosaminoglycans produced in Chinese hamster ovary (CHO) cells suggested that multiple heparanases are necessary for the formation of the short heparan sulphate chains [Bame and Robson (1997) J. Biol. Chem. 272, 2245-2251]. We examined whether this is the case by purifying heparanase activity from CHO cell homogenates. Based on their ability to bind ion-exchange resins and their elution from gel-filtration columns, four separate heparanase activities were partially purified. All four activities cleave free glycosaminoglycans over a broad pH range of 3.5-6.0 or 6. 5, suggesting that they act in the endosomal/lysosomal pathway. The sizes of the short heparan sulphate chains generated by the partially purified heparanases ranged from 6 to 9 kDa, and for two of the activities the product size is pH-dependent. Three of the four activities degrade proteoglycans as well as the free glycosaminoglycan chain. Interestingly, all four enzymes generate short glycosaminoglycans with a sulphate-rich, modified domain at the non-reducing end of the newly formed chain. Since our previous studies showed that in CHO cells there is also a population of short heparan sulphates with a modified domain at the reducing end of the chain, this suggests that there may be another heparanase in CHO cells that was not purified. Alternatively, our findings suggest that the formation of short heparan sulphate glycosaminoglycans inside CHO cells may be a result of the concerted action of multiple heparanases, and may depend on the proportions of the different enzymes and the environment in which the chains are degraded.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806900      PMCID: PMC1219857          DOI: 10.1042/bj3360191

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Acidification of morphologically distinct endosomes in mutant and wild-type Chinese hamster ovary cells.

Authors:  D J Yamashiro; F R Maxfield
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

2.  Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate.

Authors:  D Marchetti; S Liu; W C Spohn; D D Carson
Journal:  J Biol Chem       Date:  1997-06-20       Impact factor: 5.157

Review 3.  The extended family of proteoglycans: social residents of the pericellular zone.

Authors:  J T Gallagher
Journal:  Curr Opin Cell Biol       Date:  1989-12       Impact factor: 8.382

4.  Purification and properties of human platelet heparitinase.

Authors:  G M Oosta; L V Favreau; D L Beeler; R D Rosenberg
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

5.  Substrate specificity of a heparan sulfate-degrading endoglucuronidase from human placenta.

Authors:  U Klein; K von Figura
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1979-10

Review 6.  Heparanases and tumor metastasis.

Authors:  M Nakajima; T Irimura; G L Nicolson
Journal:  J Cell Biochem       Date:  1988-02       Impact factor: 4.429

7.  Nonlysosomal processing of cell-surface heparan sulfate proteoglycans. Studies of I-cells and NH4Cl-treated normal cells.

Authors:  J H Brauker; J L Wang
Journal:  J Biol Chem       Date:  1987-09-25       Impact factor: 5.157

8.  Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.

Authors:  Y Matzner; M Bar-Ner; J Yahalom; R Ishai-Michaeli; Z Fuks; I Vlodavsky
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase.

Authors:  K J Bame; J D Esko
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

10.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation.

Authors:  O Saksela; D Moscatelli; A Sommer; D B Rifkin
Journal:  J Cell Biol       Date:  1988-08       Impact factor: 10.539

View more
  4 in total

1.  Characterization of a novel intracellular heparanase that has a FERM domain.

Authors:  Karen J Bame; Indumati Venkatesan; Jean Dehdashti; Jeffrey McFarlane; Rebecca Burfeind
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

2.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

3.  Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T.

Authors:  Yu-Jie Yang; Ya-Li Zhang; Xu Li; Han-Lei Dan; Zhuo-Sheng Lai; Ji-De Wang; Qun-Ying Wang; Hai-Hong Cui; Yong Sun; Ya-Dong Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

4.  The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin.

Authors:  Edward N Harris; Janet A Weigel; Paul H Weigel
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.